Abstract
Focus on non-classical effects and possible less side effects of treatment with nutritional vitamin D, raises the expectation of possible benefits from treating chronic kidney disease (CKD) patients with ergocalciferol (vitamin D2). Treatment with 1,25(OH)2 vitamin D (calcitriol) induces elevated fibroblast growth factor 23 (FGF23), while epidemiological studies have found positive effects of nutritional and 25(OH)vitamin D on mortality in CKD. Disturbed mineral homeostasis in CKD is correlated to adverse outcome and cardiovascular mortality. The objective was to examine the possible effects of treatment with high doses of ergocalciferol on parameters of mineral homeostasis in predialysis CKD patients.
| Original language | English |
|---|---|
| Journal | Scandinavian Journal of Clinical & Laboratory Investigation |
| Volume | 73 |
| Issue number | 2 |
| Pages (from-to) | 107-16 |
| Number of pages | 10 |
| ISSN | 0036-5513 |
| DOIs | |
| Publication status | Published - Mar 2013 |
Keywords
- Adult
- Bone and Bones
- Calcium
- Creatinine
- Ergocalciferols
- Female
- Fibroblast Growth Factors
- Homeostasis
- Humans
- Male
- Parathyroid Hormone
- Phosphates
- Renal Insufficiency, Chronic
- Treatment Outcome
- Vitamins
Fingerprint
Dive into the research topics of 'Ergocalciferol treatment and aspects of mineral homeostasis in patients with chronic kidney disease stage 4-5'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS